Sophia Karagiannis

List of Publications by Year in descending order

142 papers	5,220 citations	71102 41 h-index	102487 66 g-index
147 all docs	147 docs citations	147 times ranked	7821 citing authors

#	Article	IF	Citations
1	B Lymphocytes Accumulate and Proliferate in Human Skin at Sites of Cutaneous Antigen Challenge. Journal of Investigative Dermatology, 2022, 142, 726-731.e4.	0.7	2
2	Clinical and Translational Significance of Basophils in Patients with Cancer. Cells, 2022, 11, 438.	4.1	14
3	AllergoOncology: Danger signals in allergology and oncology: AÂEuropean Academy of Allergy and Clinical Immunology (EAACI) Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2594-2617.	5.7	5
4	BRAF inhibitors and their immunological effects in malignant melanoma. Expert Review of Clinical Immunology, 2022, 18, 347-362.	3.0	8
5	Novel drug-target interactions via link prediction and network embedding. BMC Bioinformatics, 2022, 23, 121.	2.6	6
6	Antibodies as biomarkers for cancer risk: a systematic review. Clinical and Experimental Immunology, 2022, 209, 46-63.	2.6	13
7	Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. Clinical and Experimental Immunology, 2022, 209, 4-21.	2.6	7
8	Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. Clinical and Experimental Immunology, 2022, 207, 84-94.	2.6	4
9	Special Issue â€œAntibody Engineering for Cancer Immunotherapyâ€. Antibodies, 2022, 11, 29.	2.5	1
10	Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nature Communications, 2022, 13, .	12.8	17
11	Immune cellâ€“antibody interactions in health and disease. Clinical and Experimental Immunology, 2022, 209, 1-3.	2.6	4
12	CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. Cancers, 2022, 14, 3361.	3.7	6
13	PIPEâ€cloned human IgE and IgG4 antibodies: New tools for investigating cow's milk allergy and tolerance. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1553-1556.	5.7	3
14	IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer. OncoImmunology, 2021, 10, 1880687.	4.6	18
15	In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart. OncoImmunology, 2021, 10, 1966970.	4.6	2
16	Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples. , 2021, , 329-350.		0
17	Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell, 2021, 39, 257-275.e6.	16.8	93
18	Combined antiâ€PDâ€1 and antiâ€CTLAâ€4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. European Journal of Immunology, 2021, 51, 544-556.	2.9	71

#	Article	IF	Citations
19	Utilizing Immunocytokines for Cancer Therapy. Antibodies, 2021, 10, 10.	2.5	24
20	Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. , 2021, 9, e002140.		10
21	Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer. British Journal of Cancer, 2021, 125, 748-758.	6.4	15
22	Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 4290-4304.	0.9	40
23	Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. , 2021, 9, e002673.		5
24	Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments. Cancers, 2021, 13, 4460.	3.7	15
25	Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study. BMC Immunology, 2021, 22, 61.	2.2	7
26	Is there a role for physical activity when treating patients with cancer with immune checkpoint inhibitors? Protocol for a scoping review. BMJ Open, 2021, 11, e046052.	1.9	1
27	Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors. Antibodies, 2021, 10, 44.	2.5	9
28	Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician. Cancers, 2021, 13, 5625.	3.7	8
29	In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model. MAbs, 2020, 12, 1685349.	5.2	11
30	WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion. Nature Communications, 2020, 11, 5315.	12.8	59
31	IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype. Cancers, 2020, 12, 3376.	3.7	15
32	The Role of IgG4 in the Fine Tuning of Tolerance in IgE-Mediated Allergy and Cancer. International Journal of Molecular Sciences, 2020, 21, 5017.	4.1	36
33	AllergoOncology: ultra-low IgE, a potential novel biomarker in cancerâ€"a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). Clinical and Translational Allergy, 2020, 10, 32.	3.2	40
34	IgE Antibodies against Cancer: Efficacy and Safety. Antibodies, 2020, 9, 55.	2.5	17
35	Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG1 and IgG4 against the Major Birch Pollen Allergen Bet v 1. International Journal of Molecular Sciences, 2020, 21, 5693.	4.1	3
36	Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs). Scientific Reports, 2020, 10, 8869.	3.3	11

#	Article	IF	Citations
37	Association of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 527-538.	2.5	13
38	Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study. Frontiers in Oncology, 2020, 10, 263.	2.8	7
39	Dysregulated Antibody, Natural Killer Cell and Immune Mediator Profiles in Autoimmune Thyroid Diseases. Cells, 2020, 9, 665.	4.1	18
40	Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome. Cells, 2020, 9, 1631.	4.1	26
41	Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an antiâ€tumor IgE therapeutic candidate. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2069-2073.	5.7	14
42	Mechanisms of checkpoint inhibition-induced adverse events. Clinical and Experimental Immunology, 2020, 200, 141-154.	2.6	33
43	Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. Cancer Cell, 2020, 37, 85-103.e9.	16.8	91
44	Harnessing Therapeutic IgE Antibodies to Re-educate Macrophages against Cancer. Trends in Molecular Medicine, 2020, 26, 615-626.	6.7	17
45	A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma. Cancers, 2020, 12, 1029.	3.7	22
46	Epinephrine drives human M2a allergic macrophages to a regulatory phenotype reducing mast cell degranulation in vitro. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2939-2942.	5.7	5
47	B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. Frontiers in Immunology, 2020, 11, 622442.	4.8	39
48	Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer. Cancer Research, 2020, 80, CT141-CT141.	0.9	13
49	AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice. World Allergy Organization Journal, 2019, 12, 100044.	3.5	16
50	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. Cancer Epidemiology, 2019, 62, 101584.	1.9	4
51	Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. BMC Cancer, 2019, 19, 858.	2.6	30
52	Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment. Cell, 2019, 176, 757-774.e23.	28.9	117
53	Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. OncoImmunology, 2019, 8, e1593811.	4.6	20
54	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Frontiers in Immunology, 2019, 10, 453.	4.8	177

#	Article	IF	Citations
55	IgE Antibodies: From Structure to Function and Clinical Translation. Antibodies, 2019, 8, 19.	2.5	62
56	IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states. EBioMedicine, 2019, 43, 67-81.	6.1	49
57	AllergoOncology: Expression platform development and functional profiling of an antiâ€HER2 IgE antibody. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1985-1989.	5.7	14
58	Fast generation of IgE, IgG1 and IgG4 by PIPE cloning sharing the same variable region to the major birch pollen allergen Bet v 1. Journal of Allergy and Clinical Immunology, 2019, 143, AB186.	2.9	0
59	Fast and efficient cloning of human IgE, IgG1 and IgG4 antibodies specific for beta-lactoglobulin from cow milk by Polymerase Incomplete Primer Extension (PIPE). Journal of Allergy and Clinical Immunology, 2019, 143, AB260.	2.9	0
60	Serum IgG Is Associated With Risk of Melanoma in the Swedish AMORIS Study. Frontiers in Oncology, 2019, 9, 1095.	2.8	5
61	In Planta Glycan Engineering and Functional Activities of IgE Antibodies. Frontiers in Bioengineering and Biotechnology, 2019, 7, 242.	4.1	19
62	AllergoOncology: Microbiota in allergy and cancerâ€”A European Academy for Allergy and Clinical Immunology position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1037-1051.	5.7	17
63	Abstract A095: Discovering the immune profiles of a novel antifolate receptor alpha IgE antibody associated with monocyte-mediated antitumor functions. , 2019, , .		0
64	An immunologically relevant rodent model demonstrates safety of therapy using a tumourâ€specific IgE. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2328-2341.	5.7	24
65	Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology. Journal of Allergy and Clinical Immunology, 2018, 141, 1519-1523.e9.	2.9	19
66	Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). OncoImmunology, 2018, 7, e1395127.	4.6	117
67	AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 328-340.	5.7	54
68	Anti-Folate Receptor Alphaâ€“Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. Clinical Cancer Research, 2018, 24, 5098-5111.	7.0	65
69	Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells. Frontiers in Immunology, 2018, 9, 493.	4.8	14
70	AllergoOncology: Generating a canine anticancer IgE against the epidermal growth factor receptor. Journal of Allergy and Clinical Immunology, 2018, 142, 973-976.e11.	2.9	14
71	Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody. Oncotarget, 2018, 9, 19026-19038.	1.8	30
72	Abstract LB-001: Development and evaluation of T-Zap: a novel antibody-drug conjugate for the treatment of Her2 positive breast cancer. , 2018, , .		1

#	Article	IF	Citations
73	Antibody Therapeutics for Ovarian Carcinoma and Translation to the Clinic. , 2018, , .		0
74	Anti-Folate Receptor-Î± IgE but not IgG Recruits Macrophages to Attack Tumors via TNFÎ±/MCP-1 Signaling. Cancer Research, 2017, 77, 1127-1141.	0.9	58
75	B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment. OncoImmunology, 2017, 6, e1294296.	4.6	51
76	Recombinant plant-derived human IgE glycoproteomics. Journal of Proteomics, 2017, 161, 81-87.	2.4	16
77	Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer. Cancer Research, 2017, 77, 2779-2783.	0.9	42
78	AllergoOncology: IgE- and IgG 4 -mediated immune mechanisms linking allergy with cancer and their translational implications. Journal of Allergy and Clinical Immunology, 2017, 140, 982-984.	2.9	26
79	AllergoOncology â€“ the impact of allergy in oncology: <scp>EAACI</scp> position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 866-887.	5.7	68
80	An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment. Cell Reports, 2017, 20, 757-770.	6.4	118
81	Atopy and prostate cancer: Is there a link between circulating levels of IgE and PSA in humans?. Cancer Immunology, Immunotherapy, 2017, 66, 1557-1562.	4.2	4
82	Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. Frontiers in Immunology, 2017, 8, 1112.	4.8	17
83	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. Oncotarget, 2017, 8, 78174-78192.	1.8	75
84	Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types. Frontiers in Immunology, 2017, 8, 1911.	4.8	87
85	Targeting folate receptor alpha for cancer treatment. Oncotarget, 2016, 7, 52553-52574.	1.8	308
86	Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival. OncoImmunology, 2016, 5, e1154250.	4.6	34
87	355 A human in vivo model of a cutaneous memory B cell immune response to skin antigen challenge. Journal of Investigative Dermatology, 2016, 136, S221.	0.7	0
88	483 Alternative activation of cutaneous B cells and IgG antibody subclass polarisation in melanoma. Journal of Investigative Dermatology, 2016, 136, S243.	0.7	0
89	Development of downstream processing to minimize betaâ€glucan impurities in GMPâ€manufactured therapeutic antibodies. Biotechnology Progress, 2016, 32, 1494-1502.	2.6	14
90	Beta-glucan contamination of pharmaceutical products: How much should we accept?. Cancer Immunology, Immunotherapy, 2016, 65, 1289-1301.	4.2	39

#	Article	IF	Citations
91	Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs, 2016, 8, 1437-1455.	5.2	15
92	IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. Scientific Reports, 2016, 6, 29736.	3.3	52
93	IgG4 Characteristics and Functions in Cancer Immunity. Current Allergy and Asthma Reports, 2016, 16, 7.	5.3	76
94	Abstract A089: The circulating memory B cell compartment of breast cancer patients is depleted in comparison with healthy volunteers. , 2016, , .		0
95	Abstract A009: IgG4: a new tool to predict the risk of disease progression in melanoma. , 2016, , .		0
96	Abstract A090: Exploring folate receptor Î± immunotherapy of breast carcinomas: Human monocytic cell-mediated killing triggered by IgG1 and IgE antibodies. , 2016, , .		0
97	Abstract A116: IgG antibody switching and clonal expansion in melanoma and normal skin microenvironments. , 2016, , .		0
98	Tumour-associated macrophage polarisation and re-education with immunotherapy. Frontiers in Bioscience - Elite, 2015, 7, 334-351.	1.8	0
99	Revisiting the role of B cells in skin immune surveillance. Trends in Immunology, 2015, 36, 102-111.	6.8	73
100	Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis. Lancet, The, 2015, 385, S53.	13.7	9
101	Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. OncoImmunology, 2015, 4, e1032492.	4.6	53
102	TGF-Î²-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination. Current Biology, 2015, 25, 2899-2914.	3.9	106
103	Tumour-associated macrophage polarisation and re-education with immunotherapy. Frontiers in Bioscience - Elite, 2015, 7, 334-351.	1.8	41
104	Abstract 1324: A translational platform to design antibodies targeting triple negative breast cancer-specific antigens for cancer immunotherapy. , 2015, , .		0
105	Abstract 1459: Patient-derived xenograft models of breast cancer with human immune components. , 2015, , .		0
106	A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs, 2014, 6, 755-763.	5.2	44
107	Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma. Molecular Cancer Therapeutics, 2014, 13, 2769-2783.	4.1	73
108	Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency. MAbs, 2014, 6, 509-522.	5.2	12

#	Article	IF	Citations
109	Î±-Melanocyte-stimulating hormone: a protective peptide against chemotherapy-induced hair follicle damage?. British Journal of Dermatology, 2014, 170, 956-960.	1.5	25
110	IgE immunotherapy. MAbs, 2014, 6, 54-72.	5.2	46
111	Evaluating biomarkers in melanoma. Frontiers in Oncology, 2014, 4, 383.	2.8	38
112	Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nature Communications, 2014, 5, 4255.	12.8	140
113	Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review). Oncology Reports, 2014, 32, 875-886.	2.6	37
114	A tool kit for rapid cloning and expression of recombinant antibodies. Scientific Reports, 2014, 4, 5885.	3.3	85
115	Epidemiological associations of allergy, IgE and cancer. Clinical and Experimental Allergy, 2013, 43, 1110-1123.	2.9	73
116	IgG4 antibodies and cancer-associated inflammation. OncoImmunology, 2013, 2, e24889.	4.6	28
117	Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment. Microbiology Spectrum, 2013, 1, .	3.0	4
118	Abstract B65: IgG4 subclass antibodies impair antitumor immunity in melanoma.. , 2013, , .		2
119	IgG4 subclass antibodies impair antitumor immunity in melanoma. Journal of Clinical Investigation, 2013, 123, 1457-1474.	8.2	181
120	Abstract B46: Immunotherapy of solid tumors with IgE antibodies: Paradigm of a novel concept towards clinical application.. , 2013, , .		0
121	Advances in the treatment of melanoma. Clinical Medicine, 2012, 12, 168-171.	1.9	12
122	Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. Journal of Experimental Medicine, 2012, 209, 935-945.	8.5	212
123	Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunology, Immunotherapy, 2012, 61, 1547-1564.	4.2	55
124	Immunotherapy for melanoma. Expert Review of Dermatology, 2012, 7, 51-68.	0.3	0
125	Toward Prediction of Immune Mechanisms and Design of Immunotherapies in Melanoma. Critical Reviews in Biomedical Engineering, 2012, 40, 279-294.	0.9	8
126	Abstract 2524: Antibodies of the IgG and IgE classes against the melanoma-associated antigen HMW-MAA: Investigating a new therapeutic approach. , 2012, , .		0

#	Article	IF	Citations
127	Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcÉ›Rlâ€mediated basophil activation by a tumourâ€specific IgE antibody to evaluate the risk of type I hypersensitivity. Clinical and Experimental Allergy, 2011, 41, 1400-1413.	2.9	38
128	Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies. PLoS ONE, 2011, 6, e19330.	2.5	72
129	Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes and Control, 2010, 21, 1657-1667.	1.8	49
130	IgE Interacts with Potent Effector Cells Against Tumors: ADCC and ADCP. , 2010, , 185-213.		6
131	Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunology, Immunotherapy, 2009, 58, 915-930.	4.2	117
132	AllergoOncology: the role of IgEâ€mediated allergy in cancer. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1255-1266.	5.7	192
133	IgE-Antibody-Dependent Immunotherapy of Solid Tumors: Cytotoxic and Phagocytic Mechanisms of Eradication of Ovarian Cancer Cells. Journal of Immunology, 2007, 179, 2832-2843.	0.8	117
134	Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. Journal of Immunological Methods, 2007, 323, 160-171.	1.4	45
135	Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunology, Immunotherapy, 2007, 57, 247-263.	4.2	65
136	Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. European Journal of Immunology, 2003, 33, 1030-1040.	2.9	106
137	Endocytosis and recycling of the complex between CD23 and HLA-DR in human B cells. Immunology, 2001, 103, 319-331.	4.4	61
138	Comparison of IgE and IgG antibody-dependent cytotoxicityin vitro and in a SCID mouse xenograft model of ovarian carcinoma. European Journal of Immunology, 1999, 29, 3527-3537.	2.9	104
139	Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. , 1999, 29, 3527.		1
140	Colocalisation of insulin and IGF-1 receptors in cultured rat sensory and sympathetic ganglion cells. Journal of Anatomy, 1997, 191, 431-440.	1.5	24
141	Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment. , 0, , 75-102.		0
142	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. Frontiers in Oncology, 0, 9, .	2.8	0